{"id":"W4310290800","doi":"10.1007/s10557-022-07392-2","title":"Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study","year":2022,"lang":"en","type":"article","venue":"Cardiovascular Drugs and Therapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa; University Health Network; Toronto General Hospital; St. Michael's Hospital","funders":"Duke Clinical Research Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Regeneron Pharmaceuticals; Bayer Canada; Esperion Therapeutics; Servier; Novo Nordisk; Daiichi-Sankyo; Boston Scientific Corporation; Pfizer; York University; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; AstraZeneca; CSL Behring; Eli Lilly Canada; AstraZeneca Canada; University of Toronto; Heart and Stroke Foundation of Canada; American Regent; Sanofi; Amgen; HLS Therapeutics; U.S. Department of Health and Human Services","keywords":"Medicine; Percutaneous coronary intervention; Conventional PCI; Kidney disease; Internal medicine; Clinical endpoint; Renal function; Myocardial infarction; Post-hoc analysis; Cardiology; Randomized controlled trial; Population; P2Y12","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009848021,0.0002440102,0.001086469,0.0003110381,0.0001121355,0.00000984513,0.0001406995,0.00006114321,0.0001566748],"category_scores_gemma":[0.0000332171,0.0001830441,0.002209207,0.0008193243,0.0002077772,0.00006701688,0.0001132908,0.0001799798,1.784761e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001056542,"about_ca_system_score_gemma":0.0001777179,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001872671,"about_ca_topic_score_gemma":0.00000495876,"domain_scores_codex":[0.9972357,0.0007639233,0.0006084654,0.0004313385,0.0007721563,0.0001884844],"domain_scores_gemma":[0.9986337,0.00007195333,0.0001909513,0.0008220121,0.0001548786,0.0001265291],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.04401111,0.00320124,0.3496982,0.000473726,0.07352881,0.0002938205,0.009187349,0.00741179,0.009105714,0.00004359937,0.00001447067,0.5030302],"study_design_scores_gemma":[0.01625574,0.001511933,0.9727089,0.0001230878,0.004435373,0.00009830245,0.001709277,0.0004423211,0.0003331276,0.00001606233,0.002133296,0.000232545],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8419311,0.1564617,0.00003741973,0.00005155608,0.00006898052,0.00128721,0.0001352215,0.00001228221,0.00001453148],"genre_scores_gemma":[0.9851692,0.01446608,0.000007784857,0.00008851377,0.00004778534,0.00006181627,0.0001041073,0.00003283431,0.00002184025],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6230108,"threshold_uncertainty_score":0.7464323,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008144742595637439,"score_gpt":0.2386803708205855,"score_spread":0.2305356282249481,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}